Envafolimab  (Synonyms: 恩沃利单抗; ASC 22; KN 035)

Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC₅₀ value of 5.25?nM. Envafolimab has the potential for the research of solid tumors^[1][2][3].

[G1 VH-h-CH2-CH3]-dimer

Chimeric

Envafolimab (0-2.51 nM) induces T-cell cytokine (IFN-γ) production in a dose- and time-dependent manner^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Envafolimab (0.18-0.92 mg/kg; i.p.; four times over 2 weeks) shows antitumor activity with a half-life of ~72?h in NOD-SCID mice (A375 cells)^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2102192-68-5

液体

Colorless to light yellow

恩弗利单抗，恩沃利单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  [G1 VH-h-CH2-CH3]-dimer

• [1]. Papadopoulos KP, et al. First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors. Oncologist. 2021 Sep;26(9):e1514-e1525.  [Content Brief]

  [2]. Akinleye A, et al. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019 Sep 5;12(1):92.  [Content Brief]

  [3]. Zhang F, Wei H, Wang X, Bai Y, Wang P, Wu J, Jiang X, Wang Y, Cai H, Xu T, Zhou A. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov. 2017 Mar 7;3:17004.  [Content Brief]